Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda’s FY2021 Sales Up 11.6%; Weak Yen Tailwind for Revenue, but Drags Profits
May 12, 2022
- Shionogi Books 110 Billion Yen Sales for Yet-to-Be-Approved COVID Pill, Vaccine: FY2022 Outlook
May 12, 2022
- Opdivo Projected to Grow 38% to 155 Billion Yen, but Ono Chief Sees No Re-Pricing
May 12, 2022
- Meiji Kicks Off Japanese PI Study of Stelara Biosimilar
May 12, 2022
- Ono Nets 16.8% Sales Growth on Opdivo, Forxiga; 400 Billion-Plus Yen Eyed for FY2022
May 12, 2022
- Asahi Kasei Sues Sawai over Manufacturing Method of Teribone Generic
May 11, 2022
- Kyowa Kirin’s Q1 Sales Up 8.2% on Robust Overseas Performance Driven by Crysvita
May 11, 2022
- Jardiance Will Come Back as No. 1 in Japan SGLT2 Space after CKD Launch: NBI Chair
May 11, 2022
- Healios, NCC to Evaluate Antitumor Effects of eNK Cells
May 11, 2022
- Santen Snags China OK for Vernal Keratoconjunctivitis Drug
May 11, 2022
- Eisai Completes Rolling Submission for Lecanemab in US
May 11, 2022
- Eisai Sets to File Ultra-High Dose Mecobalamin for ALS in Japan
May 11, 2022
- RaQualia’s Acid Reducer Tegoprazan Now Available in China
May 10, 2022
- 1st Dose of COVID-19 Jab Given in Adult and Pediatric Trials: KM Biologics/Meiji
May 10, 2022
- Kyoto University’s BMS Building Breaks Ground for I/O Research with 5.5 Billion Yen Donation
May 10, 2022
- Argenx’s 1st Med in Japan Vyvgart Now Available for Generalized Myasthenia Gravis
May 10, 2022
- FDA Defers PDUFA Date for Myfembree for Endometriosis Use: Myovant/Pfizer
May 10, 2022
- Maruho Grabs Japan Rights for JAK2 Inhibitor Ruxolitinib Cream
May 9, 2022
- Sumitomo Pharma Grants Narcolepsy Drug Rights to Jazz
May 9, 2022
- Enhertu Gets Second-Line Breast Cancer Nod in US: Daiichi Sankyo/AZ
May 9, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…